Mayne Pharma Group (HAM:HG6) Beta: N/A (As of Jun. 27, 2026)


HAM:HG6 Mayne Pharma Group Ltd HAM:HG6
51 GF Score
Price €2.54
GF Value €5.77
! 3 Warning Signs
View Full Analysis

What is Mayne Pharma Group Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-27), Mayne Pharma Group's Beta is Not available.

Mayne Pharma Group  (HAM:HG6) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)

Mayne Pharma Group Beta Related Terms

Mayne Pharma Group Beta Historical Data

* Premium members only.

The historical data trend for Mayne Pharma Group's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mayne Pharma Group Beta Chart

Mayne Pharma Group Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.72 1.93 1.71 2.30 1.75

Mayne Pharma Group Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.33 2.30 0.10 1.75 0.00
HAM:HG6
51GF Score
Mayne Pharma Group Ltd HAM:HG6
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mayne Pharma Group Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Is Mayne Pharma Group (HAM:HG6) Overvalued in 2026?

Based on GuruFocus' analysis, Mayne Pharma Group stock appears to be undervalued. The current stock price of €2.54 is trading 56% below its estimated GF Value™ of €5.77.

Key valuation signals for HAM:HG6:

  • Beta: N/A
  • GF Value™: €5.77 vs. price of €2.54 (56% below fair value)
  • GF Score™: 51/100 with 3 warning signs

No single metric tells the full story. See the HAM:HG6 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Mayne Pharma Group Business Description

Other Exchanges MAYNF:USAMYX:Australia
Address 1538 Main North Road, Salisbury South, Salisbury, SA, AUS, 5106
Mayne Pharma Group Ltd is a specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals It has a Forty-year track record of innovation and success in developing oral drug delivery systems. The Company's Business consists of three operating segments being International, Women's Health and Dermatology. The Dermatologysegment distributes dermatology products (branded and generic) in the U.S. on a portfolio basis, The Women's Health segment distributes branded women's health products in the U.S. International's segment revenue and gross profit are derived principally from the Australian manufacture and sale of branded and generic pharmaceutical products.
51GF Score

Get the complete analysis for HAM:HG6

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.54
Price
€5.77
GF Value